[{"address1": "3000 Pegasus Park Drive", "address2": "Suite 1430", "city": "Dallas", "state": "TX", "zip": "75247", "country": "United States", "phone": "214 612 0000", "website": "https://www.tayshagtx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 52, "companyOfficers": [{"maxAge": 1, "name": "Mr. Sean P. Nolan", "age": 55, "title": "CEO & Chairman", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 925331, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sukumar  Nagendran M.D.", "age": 56, "title": "President, Head of Research & Development and Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 820594, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kamran  Alam CPA, M.B.A.", "age": 45, "title": "CFO & Corporate Secretary", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 573362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Hayleigh  Collins", "title": "Director of Corporate Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tracy M. Porter SPHR", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Frederick  Porter Ph.D.", "title": "Chief of Staff & Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  McGinnis M.P.H.", "title": "Chief Patient Advocacy & External Affairs Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  McAuliffe", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven  Gray Ph.D.", "title": "Chief Scientific Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Berge  Minassian M.D.", "title": "Chief Medical Advisor of UT Southwestern Gene Therapy Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.165, "open": 2.17, "dayLow": 2.07, "dayHigh": 2.31, "regularMarketPreviousClose": 2.165, "regularMarketOpen": 2.17, "regularMarketDayLow": 2.07, "regularMarketDayHigh": 2.31, "beta": 0.472, "forwardPE": -4.869565, "volume": 28053032, "regularMarketVolume": 28053032, "averageVolume": 2724974, "averageVolume10days": 7358790, "averageDailyVolume10Day": 7358790, "bid": 2.21, "ask": 2.26, "bidSize": 900, "askSize": 5300, "marketCap": 451088992, "fiftyTwoWeekLow": 0.613, "fiftyTwoWeekHigh": 4.32, "priceToSalesTrailing12Months": 31.865568, "fiftyDayAverage": 2.9412, "twoHundredDayAverage": 2.381075, "currency": "USD", "enterpriseValue": 356323936, "floatShares": 111661131, "sharesOutstanding": 201379008, "sharesShort": 14719168, "sharesShortPriorMonth": 17042982, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0787, "heldPercentInsiders": 0.17222999, "heldPercentInstitutions": 0.69835, "shortRatio": 7.0, "shortPercentOfFloat": 0.1071, "impliedSharesOutstanding": 187018000, "bookValue": 0.288, "priceToBook": 7.777778, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -118005000, "trailingEps": -0.78, "forwardEps": -0.46, "enterpriseToRevenue": 25.171, "enterpriseToEbitda": -4.581, "52WeekChange": 2.5499208, "SandP52WeekChange": 0.22553468, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "TSHA", "underlyingSymbol": "TSHA", "shortName": "Taysha Gene Therapies, Inc.", "longName": "Taysha Gene Therapies, Inc.", "firstTradeDateEpochUtc": 1600954200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "fa02d192-bc05-33bd-8c2b-2973d0bcc5d6", "messageBoardId": "finmb_665948579", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.24, "targetHighPrice": 9.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.77, "targetMedianPrice": 7.0, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 123980000, "totalCashPerShare": 0.663, "ebitda": -77780000, "totalDebt": 61383000, "quickRatio": 3.209, "currentRatio": 3.38, "totalRevenue": 14156000, "debtToEquity": 113.991, "revenuePerShare": 0.09, "returnOnAssets": -0.38858002, "returnOnEquity": -6.06694, "freeCashflow": -57143752, "operatingCashflow": -72631000, "revenueGrowth": -0.275, "grossMargins": 1.0, "operatingMargins": -7.13281, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-30"}]